The Broad's outlook in cancer

When the Broad Institute of MIT and Harvard launched its Center for the Science of Therapeutics to develop new therapies for hard-to-hit targets and test them in the clinic, it lacked funds to take discoveries all the way to approval. The center's new collaboration with Bayer AGfills that gap for cancer assets and comes on the heels of its infectious disease arrangement with AstraZeneca plc.

Under the five-year collaboration, the partners will explore each other's compound libraries, share screening platforms and contribute medicinal chemistry expertise to discover new small molecules for cancer...